Alios BioPharma Lands $32,000,000 Series A Funding Round

  • Feed Type
  • Date
    6/11/2009
  • Company Name
    Alios BioPharma
  • Mailing Address
    101 A Hickey Boulevard South San Francisco, CA 94080
  • Company Description
    Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
  • Website
    http://www.aliosbiopharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Company to Develop a Portfolio of Novel Antiviral Agents.
  • M&A Terms
  • Venture Investor
    GlaxoSmithKline
  • Venture Investor
    SR One

Trending on Xconomy